Bristol-Myers Squibb Co vs Utilities Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Utilities Select Sector SPDR Fund trades at $45.69. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| BMY | XLU | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $47.73 |
52-Week Low | $42.60 | $40.99 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XLU trades at $45.72, up 0.68% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF benefits from growing electricity demand driven by AI data centers and clean energy transitions, positioning utilities as both defensive and growth-oriented investments. Recent news highlights XLU's role in powering AI infrastructure, with top holdings securing long-term power agreements with major tech firms.
Outlook remains positive due to structural power demand growth, though risks include regulatory changes and grid capacity constraints. Wall Street sentiment is bullish with strong institutional interest, but investors should monitor interest rate sensitivity and execution of capital expenditure plans for new power generation assets.
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →